PROT# OSI4263s//NU 0714: A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition with Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients with Metastatic Colorectal Cancer

Project: Research project

Project Details

StatusFinished
Effective start/end date7/9/09 → 12/31/17

Funding

  • Genentech, Inc. (OSI4263s//NU 0714)